350-27-6

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Fluoro-4-methoxyphenacyl bromide is used as a reagent in the protection and deprotection of amino acids in peptide synthesis, facilitating the development of novel bioactive molecules and pharmaceuticals.
Used in Agrochemical Production:
FMOCB is used as a key intermediate in the production of agrochemicals, contributing to the creation of effective and innovative products for agricultural applications.
Used in Organic Synthesis:
3-Fluoro-4-methoxyphenacyl bromide is used as a building block for the creation of diverse chemical structures, with potential applications in drug discovery and development, highlighting its importance in advancing the field of medicinal chemistry.

Upstream product

• 321-28-8 1-fluoro-2-methoxybenzene 
• 598-21-0 2-Bromoacetyl bromide 
• 455-91-4 1-(3-fluoro-4-methoxyphenyl)ethanone 

Downstream Products

• 397-42-2 2-(3-fluoro-4-methoxy-phenyl)-7-methyl-indolizine 
• 802558-44-7 1-(3-fluoro-4-methoxy-phenyl)-2-(2-imino-thiazolidin-3-yl)-ethanone 
• 1545-89-7 6-(3-fluoro-4-methoxy-phenyl)-imidazo[2,1-b]thiazole 
• 1496-21-5 ethyl-[4-(3-fluoro-4-methoxy-phenyl)-thiazol-2-yl]-amine 
• 78864-20-7 [5-(3-fluoro-4-methoxy-phenyl)-thiazol-2-yl]-(2-methoxy-phenyl)-amine 
• 1025844-62-5 2-[2-(3-Fluoro-4-methoxy-phenyl)-2-oxo-ethyl]-2-[2-(4-methanesulfonyl-phenyl)-2-oxo-ethyl]-malonic acid dimethyl ester 
• 186093-84-5 2-(3-Fluoro-4-methoxy-benzoyl)-benzofuran-5-carbaldehyde 
• 186093-95-8 5-[2-(3-Fluoro-4-methoxy-benzoyl)-benzofuran-5-ylmethyl]-thiazolidine-2,4-dione 
• 1373762-78-7 7-({5-[(3-fluoro-4-methoxyphenyl)-2-oxoethylsulfanyl]-1,3,4-oxadiazol-2-yl}methoxy)-4-methylchromen-2-one 
• 956027-75-1 tert-butyl (3R)-3-({4-[6-(4-fluoro-3-methoxyphenyl)imidazo[2,1-b][1,3]thiazol-5-yl]pyrimidin-2-yl}amino)piperidine-1-carboxylate 
• 956027-78-4 tert-butyl 4-({4-[6-(4-fluoro-3-methoxyphenyl)imidazo[2,1-b][1,3]thiazol-5-yl]pyrimidin-2-yl}amino)piperidine-1-carboxylate 
• 956027-74-0 3-(dimethylamino)-1-[6-(4-fluoro-3-methoxyphenyl)imidazo[2,1-b][1,3]thiazol-5-yl]prop-2-en-1-one 
• 956027-73-9 1-[6-(4-fluoro-3-methoxyphenyl)imidazo[2,1-b][1,3]thiazol-5-yl]ethanone 

Relevant academic research and scientific papers

SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES

The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

ANTIBACTERIAL COMPOUNDS

The present invention relates to compounds of general formula (II),to compositions comprising these compounds and to methods of treating Enterobacteriaceae bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Enterobacteriaceae.

Synthesis and bioevaluation of N,4-diaryl-1,3-thiazole-2-amines as tubulin inhibitors with potent antiproliferative activity

A series of N,4-diaryl-1,3-thiazole-2-amines containing three aromatic rings with an amino linker were designed and synthesized as tubulin inhibitors and evaluated for their antiproliferative activity in three human cancer cell lines. Most of the target compounds displayed moderate antiproliferative activity, and N-(2,4-dimethoxyphenyl)-4-(4-methoxyphenyl)-1,3-thiazol-2-amine (10s) was determined to be the most potent compound. Tubulin polymerization and immunostaining experiments revealed that 10s potently inhibited tubulin polymerization and disrupted tubulin microtubule dynamics in a manner similar to CA-4. Moreover, 10s effectively induced SGC-7901 cell cycle arrest at the G2/M phase in both concentrationand time-dependent manners. The molecular docking results revealed that 10s could bind to the colchicine binding site of tubulin.

RAF INHIBITORS AND THEIR USES

The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAFV600E. The compounds are useful for the t

DIAMINOTHIAZOLES

The present invention is directed to novel diaminothiazoles of formula These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.

Diaminothiazoles having antiproliferative activity

Disclosed are novel diaminothiazoles that are selective inhibitors of Cdk4. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds as well as intermediates useful in the preparation of the compounds.

Pyrrole derivatives and medicinal composition

The invention relates to a pharmaceutical composition comprising a pyrrole derivative of the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate of either of them, as an active ingredient. STR1 (wherein R1 represents hydrogen or alkoxycar91 bonylamino, R2 represents alkyl, aryl which may be substituted, aromatic heterocyclyl which may be substituted, unsubstituted amino, monoalkylamino, dialkylamino, or cyclic amino which may be substituted; R3 represents cyano or carbamoyl; R4 represents hydrogen or alkyl; E represents alkylene; q is equal to 0 or 1, A represents methyl, aryl which may be substituted, or aromatic heterocyclyl which may be substituted). The pharmaceutical composition of the invention is effective for the treatment of pollakiuria or urinary incontinence.

Synthetic approaches to benzofuran containing Insulin Sensitivity Enhancer compounds for treatment of type II diabetes

The search for Insulin Sensitivity Enhancer (ISE) compounds, for potential use in the treatment of Type II diabetes, has led to the synthesis of compounds that contain a benzofuran spacer between an aryloyl substituent and a 2,4-thiazolidinedione pharmacophore. Sequential combination of haloacetyl aryl substrates with 5-formylsalicylaldehyde gave the desired 2-aryloyl-5-formylbenzofuran intermediates. A related class of compounds, those with a methylene tether between the aromatic moiety and the benzofuran spacer, were also prepared through this strategy.

Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: Synthesis and structure-activity relationships

A novel series of 5,6-diarylspiro[2.4]hept-5-enes was shown to provide highly potent and selective cyclooxygenase-2 (COX-2) inhibitors. A study of structure-activity relationships in this series suggests that 3,4- disubstituted phenyl analogs are generally more selective than 4-substituted phenyl analogs and that replacement of the methyl sulfone group on the 6- phenyl ring with a sulfonamide moiety results in compounds with superior in vivo pharmacological properties, although with lower COX-2 selectivity. Several compounds have been shown to possess promising pharmacological properties in adjuvant-induced arthritis and edema analgesia models. The absence of gastrointestinal (GI) toxicity at 200 mpk of several selected compounds in rats and mice corresponds well with the weak potency for inhibition of COX-1 observed in the enzyme assay. Methyl sulfone 55 and sulfonamide 24 were shown to have superior in vivo pharmacological profiles, low GI toxicity, and good oral bioavailability and duration of action.